Unlock instant, AI-driven research and patent intelligence for your innovation.

Dual agonist peptides of adiponectin receptor-1 and receptor-2 for the treatment of nonalcoholic steatohepatitis and liver fibrosis

A dual agonist, adiponectin technology, applied in the field of biochemistry, can solve the problem of no peptide drug development, etc., and achieve the effects of good biological activity, easy to scale up production, and good stability

Active Publication Date: 2020-07-28
SUN YAT SEN UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, among the drugs reported for the treatment of nonalcoholic steatohepatitis and liver fibrosis, no peptide drugs targeting adiponectin receptor-1 and adiponectin receptor-2 have been developed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual agonist peptides of adiponectin receptor-1 and receptor-2 for the treatment of nonalcoholic steatohepatitis and liver fibrosis
  • Dual agonist peptides of adiponectin receptor-1 and receptor-2 for the treatment of nonalcoholic steatohepatitis and liver fibrosis
  • Dual agonist peptides of adiponectin receptor-1 and receptor-2 for the treatment of nonalcoholic steatohepatitis and liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Embodiment 1, the synthesis of double agonist peptide

[0054] Materials: All amino acids were purchased from NovaBiochem;

[0055] Unless otherwise specified, all other reagents were of analytical grade and purchased from Sigma;

[0056] Using Protein Technologies PRELUDE 6-channel synthetic peptide synthesizer;

[0057] Phenomenex Luna C18 preparative column (46mm x 250mm) was used to purify synthetic peptides;

[0058] The high-performance liquid chromatograph is a product of Waters;

[0059] Mass spectrometry was performed using an Agilent mass spectrometer.

[0060] The compound Pep70 (structural sequence: PGLYYFD-NH2) is taken as an example to illustrate the synthesis method of the dual agonist peptide of the present invention.

[0061] a) Assembly of the main peptide chain:

[0062] According to the Fmoc / t-Bu strategy, the following synthetic peptides were synthesized on a CS336X synthetic peptide synthesizer (CS Bio, USA) at a scale of 0.25 mmol: Pro-Gly-Le...

Embodiment 2

[0071] Example 2, Cytotoxicity evaluation using the dual agonist peptide obtained in Example 1 as a test substance

[0072] Human hepatic stellate cell LX2 cell line was selected to study and observe the detection of the test substance on the proliferation and toxicity of LX2 cells.

[0073] LX2 cells were inoculated into 96-well plates and cultured with DMEM (high glucose) + 10% FBS (fetal bovine serum) + 1% double antibody medium (Thermo Fisher) at 37°C, 5% CO 2 When the cells grew to 70% confluence under the condition, different concentrations of test substances were added, and after incubation for 48 hours, CCK8 reagent was added, and the absorbance was detected at a wavelength of 450 nm.

[0074] figure 1 is the percentage of cell viability in each group, figure 1 It shows that in the concentration range of 0-1024μM, it shows that the tested cells maintain a high and basically the same level of cell activity, and the cell activity is not affected, indicating that the te...

Embodiment 3

[0075] Example 3. Using the Pep70 obtained in Example 1 and the dual agonist peptides A1-A4 as test substances to carry out the in vitro inhibitory effect experiment on fatty liver

[0076] The human hepatocellular carcinoma HepG2 cell line was selected to study and observe the improvement of the fat accumulation of HepG2 cells induced by palmitic acid (PA).

[0077] HepG2 cells were plated in 6-well plates, cultured with DMEM (high glucose) + 10% FBS + 1% double antibody medium (ThermoFisher), at 37°C, 5% CO 2 When the cells grew to 70% confluency under the same conditions, HepG2 cells were induced with palmitic acid (PA) at a final concentration of 0.25 mM for 24 h, and then 100 μM of the test substance was added, and the same volume of DMEM was added to the control group for 24 h. , Oil red O staining was performed to detect the effect of drugs on fatty degeneration cells.

[0078] figure 2 Oil red O staining photos of the test substance and the control group, the staine...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a dual agonist peptide of an adiponectin receptor-1 and receptor-2 for treating NAFLD and liver fibrosis, and a pharmaceutical composition comprising the same. The dual agonistpeptide comprises amino acid sequence: P-X2-L-Y-X5-F-X7, wherein at least one of X2, X5 and X7 is unnatural amino acid, P is proline, L is leucine, and Y is tyrosine. The dual agonist peptide of adiponectin receptor-1 and adiponectin receptor-2 in the invention can effectively treat NAFLD and liver fibrosis, and has the advantages of good biological activity, good stability and easy magnificationproduction, low cost, low toxicity, large safety window, and small dosage.

Description

technical field [0001] The present invention relates to the field of biochemical technology, in particular to a class of dual agonist peptides of adiponectin receptor-1 and adiponectin receptor-2; Use in the prevention and / or treatment of related diseases such as fibrosis. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury closely related to insulin resistance and genetic susceptibility. The disease spectrum includes nonalcoholic simple hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, liver cirrhosis, and hepatocellular carcinoma. NAFLD can not only lead to liver disease, disability and death, but also closely related to the high incidence of metabolic syndrome, type 2 diabetes, atherosclerotic cardiovascular disease and colorectal tumors. [0003] As an adipocyte complement-related protein, adiponectin consists of 244 amino acids and is divided into four regions: globular domain, collagen domain, va...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K38/08A61P1/16
Inventor 蒋先兴徐弘娇赵倩洪思华宋娜资
Owner SUN YAT SEN UNIV